Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, ON, Canada
Hannah Solomon, Catherine Brown, Ashlee Vennettilli, Aein Zarrin, Aditi Dobriyal, Linda Chen, Vivien Pat, Anthea Ho, Cindy Xin, Margaret Irwin, TIan Qi Wang, Christina Gonos, Zahra Merali, Lauren Wong, Wei Xu, Doris Howell, Geoffrey Liu
Background: In a busy DC setting, the efficiency of identifying important treatment toxicities is essential to quality care. Using a systematic approach to collecting patient-reported outcomes in the waiting rooms of DC units is one possible means of improving care while involving patients. This study reports such a pilot study, and the associated assessment of patient acceptance of this approach. Methods: 156 cancer patients over the age of 18 receiving chemotherapy treatment at Princess Margaret Cancer Centre completed a patient-reported chemotoxicity assessment using PRO-CTCAE items on tablet technology. Main symptoms assessed were: fatigue, nausea and vomiting, diarrhea and constipation, pain, aching muscles and/or joints and dysgeusia. Patient’s perception on the usefulness of PROMs and their willingness to complete such a tool routinely was assessed. Results: The median age was 53.5 (range: 19-88 years), 38% were male and 66% were Caucasian. Over 80% did not find the survey overly time consuming (or made their visit more difficult). Less than 1% were distressed by the survey questions. Over 80% reported that the survey asked the appropriate questions. While 81% considered the PROMs useful in informing their physician of their symptoms, 25% reported they would not be willing to complete the survey at each clinic visit. Another 25% were unsure of their feelings toward this approach. 93% were happy to complete the survey using tablet touchscreen technology. Conclusions: Most patients found the survey method of self-reporting one’s symptoms to be acceptable, non-distressful, and an important practice. From the patient perspective, the process of reporting one’s symptoms using tablet touchscreen technology is both simple and feasible.Yet, only 50% of patients would be willing to complete this survey at every clinic visit. Additional mixed-methods analysis looking at patient characteristics associated with acceptance/non-acceptance and willingness to complete the survey on a regular basis is ongoing and will be reported at the conference.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2023 ASCO Quality Care Symposium
First Author: Luluh Bin Dayil
2024 ASCO Annual Meeting
First Author: Peter Trask
2023 ASCO Annual Meeting
First Author: Ravi Bharat Parikh